These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26211591)

  • 1. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery.
    Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J
    Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells.
    Huang R; Sun Y; Gao Q; Wang Q; Sun B
    Anticancer Drugs; 2015 Oct; 26(9):957-63. PubMed ID: 26186063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents.
    Gao J; Liu YG; Liu R; Zingaro RA
    ChemMedChem; 2008 Jun; 3(6):954-62. PubMed ID: 18366039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery.
    Zhou Z; Badkas A; Stevenson M; Lee JY; Leung YK
    Int J Pharm; 2015 Jun; 487(1-2):81-90. PubMed ID: 25865568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery.
    Chen X; Wang M; Yang X; Wang Y; Yu L; Sun J; Ding J
    Theranostics; 2019; 9(21):6080-6098. PubMed ID: 31534538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
    Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
    J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new application of plant virus nanoparticles as drug delivery in breast cancer.
    Esfandiari N; Arzanani MK; Soleimani M; Kohi-Habibi M; Svendsen WE
    Tumour Biol; 2016 Jan; 37(1):1229-36. PubMed ID: 26286831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells.
    Noh JK; Naeem M; Cao J; Lee EH; Kim MS; Jung Y; Yoo JW
    Int J Pharm; 2016 Nov; 513(1-2):543-553. PubMed ID: 27686050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells.
    Huang R; Wang Q; Zhang X; Zhu J; Sun B
    Biomed Pharmacother; 2015 May; 72():17-23. PubMed ID: 26054670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
    Garcia AG; Nedev H; Bijian K; Su J; Alaoui-Jamali MA; Saragovi HU
    Oncogene; 2013 May; 32(20):2527-33. PubMed ID: 22797066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
    Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
    Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
    Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
    BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug.
    Avaji PG; Joo HI; Park JH; Park KS; Jun YJ; Lee HJ; Sohn YS
    J Inorg Biochem; 2014 Nov; 140():45-52. PubMed ID: 25061690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate.
    Oraki Kohshour M; Mirzaie S; Zeinali M; Amin M; Said Hakhamaneshi M; Jalili A; Mosaveri N; Jamalan M
    Chem Biol Drug Des; 2014 Mar; 83(3):259-65. PubMed ID: 24118702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
    Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
    Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Herceptin-based therapy for breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer.
    Zhang JL; Yao Q; Chen Y Wang JH; Wang H; Fan Q; Ling R; Yi J; Wang L
    Genet Mol Res; 2015 Mar; 14(1):2099-103. PubMed ID: 25867356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.